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Background: Mycoplasma pneumoniae (MP) causes community-acquired pneumonia affecting mainly children,
and tends to produce cyclic outbreaks. The widespread use of macrolides is increasing resistance rates to these
antibiotics. Molecular tools can help in diagnosis, typing and resistance detection, leading to better patient
management.
Objectives: To assess the MP genotypes and resistance pattern circulating in our area while comparing
serological and molecular diagnosis of MP.
Methods: Molecular and serological diagnosis of MP was performed in 821 samples collected in Badalona
(Barcelona, Spain) from 2013 to 2017. Multiple locus variable number tandem repeat analysis (MLVA) and
macrolide resistance detection by pyrosequencing were performed in those cases positive by PCR. Presence of
respiratory viruses and relevant clinical data were also recorded.
Results: MP was detected in 16.8% of cases by PCR, with an overall agreement with serology of 76%. Eleven
different MLVA types were identified, with 4-5-7-2 (50.1%) and 3-5-6-2 (29.2%) being the most abundant, with
the latter showing a seasonal increase during the study. A total of 8% of the strains harboured a point substitu-
tion associated with macrolide resistance, corresponding mainly to an A2063G 23S rRNA mutation and directly
related to previous macrolide therapy. Analysis of respiratory viruses showed viral coinfections in most cases.
Conclusions: Serological and molecular tools combined could improve MP diagnosis and the analysis of its
infection patterns. Macrolide resistance is associated with previous therapy. Given that MP pneumonia usually
resolves spontaneously, it should be reconsidered whether antibiotic treatment is suitable for all cases.
Introduction
Mycoplasma pneumoniae (MP) is a prevalent respiratory pathogen
that causes about 20%–40% of cases of community-acquired
pneumonia (CAP) in children and young adults, with epidemic
peaks at 3–7 year intervals worldwide.1 Serology is the gold stand-
ard, but molecular techniques offer a rapid and reliable alternative
for MP diagnosis and epidemiological surveillance. Molecular typ-
ing by P1 restriction fragment length polymorphism analysis
(RFLP)2 has been substituted by methods with higher discrimin-
atory power, such as multiple locus variable number tandem
repeat analysis (MLVA),3 allowing more accurate outbreak analysis
and epidemic strain monitoring worldwide.
Macrolides (MLs) are the first-line treatment, due to their low
side effects and convenient administration. MLs inhibit protein syn-
thesis by binding to domain V of 23S rRNA.4 Mutations in domain II
or V of 23S rRNA or in L4 and L22 ribosomal proteins have been
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described to be involved in ML resistance (MLr) in other species.5,6
In MP, the MLr in vivo is mainly driven by specific mutations in the V
domain of 23S rRNA gene, leading either to a high level resistance
profile (mutations at positions 2063 or 2064) or to a low level MLr
(transition at position 2067 or a transversion at position 2617).4,7–11
However, although no mutations in domain II could be linked to
MLr, mutations in ribosomal proteins L4 and L22 have been found
both in vitro4 and in vivo,9 although their real impact in MLr is still
unclear, so further research should be performed.
As MP culture is mainly performed in reference centres, MLr de-
termination by broth dilution tests11 is not accessible to most clin-
ical microbiology laboratories. Molecular techniques targeting the
single-copy 23S rRNA gene (such as PCR followed by high reso-
lution melting curve analysis,12–14 Sanger sequencing,15 RFLP8 or
pyrosequencing analysis16–18) have been described. As a conse-
quence of widespread ML use, resistance rates have risen from
40% in 2008 to 90%–100% in China recently.19,20 Concurrently, in
Europe, rates vary from 1% in Slovenia to up to 26% in Italy.21–26
Due to the increase in the prevalence of MLr observed recently and
the lack of data in Spain, it is imperative to improve technical tools
for detecting resistant strains without delay and to adjust the
patients’ therapy as necessary.
As there are no published data about the MP MLVA types circu-
lating in our area, this study aimed to provide insights about the
genotypes and yearly distribution found in Catalonia (Spain).
Furthermore, the evaluation of the presence of single-base muta-
tions in domain V of the 23S rRNA gene that provide MLr in our set-
ting is described, in comparison with the results described in other
countries. Additionally, the clinical performance of the molecular
technique used for MP pneumonia diagnosis was compared with
routine serological testing.
Materials and methods
Ethics, patients included, samples and collection
Written informed consent was obtained from patients’ guardians. This
study was approved by the Clinical Research Ethics Committee at Germans
Trias i Pujol University Hospital (‘Comité Ético de Investigación Clı́nica’,
CEIC). Samples collected included nasopharyngeal aspirates and sera. A
total of 821 nasopharyngeal samples from 774 individuals were obtained
between April 2013 and January 2017 in the Pediatric Emergency room at
the University Hospital Germans Trias i Pujol (Badalona, Spain). Samples
were divided into different groups: children (<18 years old) clinically diag-
nosed with CAP, household or school contacts from a diagnosed pneumo-
nia case and healthy volunteer subjects. Clinical data were registered by
the Pediatric Department, and microbiological results were also recorded at
the Microbiology Department.
M. pneumoniae serological and molecular diagnosis
Detection of IgG or IgM antibodies from sera was performed by a particle-
agglutination assay (SerodiaV
R
-MYCO II, Fujirebio Europe) either singly or in
two samples separated by at least 21 days in order to demonstrate a sero-
conversion. A positive result with clinical significance was defined as anti-
body levels 1/160 for single samples. For the molecular diagnosis, DNA
was extracted from nasopharyngeal aspirates using the nucliSENSV
R
easyMagV
R
platform (bioMérieux, France). MP molecular diagnosis was per-
formed using two different assays: during the first stage of the project, Real
Time PCR Realcycler M. pneumoniae/Chlamydophila pneumoniae (Progenie
molecular, Spain) was employed, whereas AnyplexV
R
2 RB5 Detection
(Seegene Inc., Korea) was used later on. Those samples in which MP DNA
was detected were further investigated for MLVA typing and MLr by pyrose-
quencing. Respiratory viruses were also tested for in all MP-positive sam-
ples, using three different methods: BinaxNOWV
R
Influenza A&B and
BinaxNOWV
R
Respiratory Syncytial virus immunochromatographic assay
(Abbott-Alere Healthcare, USA), direct immunofluorescence D3 Ultra8 DFA
Respiratory virus Screening & Identification Kit (Quidel Corporation, USA),
used until April 2014, and Anyplex II RV-16 Detection (Seegene Inc., Korea),
used from May 2014, when Anyplex was integrated into our diagnosis rou-
tine for adults and also for children with negative immunochromatographic
results.
MLVA typing
DNA from PCR-positive samples was typed using the culture-independent
MLVA approach described by Dumke and Jacobs,27 performing a nested
PCR in order to increase the sensitivity. Products from the secondary PCR
were analysed by high-resolution capillary electrophoresis (QIAxcelV
R
Advanced System, Qiagen, Germany) and subsequently purified (QIAquick
PCR Purification Kit, Qiagen). Purified PCR products were then Sanger
sequenced and the number of repeats was found by uploading the FASTA
file to the web resource Tandem Repeat Finder.28 Only four out of the five
loci (Mp13, Mp14, Mp15 and Mp16) initially described by Dégrange et al.3
were analysed due to the high variability found in locus Mp1, as described
elsewhere.29 The MLVA type is depicted as the number of repeats within
the Mp13, Mp14, Mp15 and Mp16 loci, respectively, separated by a
hyphen. Optimization of the protocol was performed using the DNA from
M. pneumoniae M129, acquired from DSMZ (German Collection of
Microorganisms and Cell Cultures, Germany).
Resistance detection by pyrosequencing
The pyrosequencing protocol was modified from Spuesens et al.16,17 Two
different assays were performed in order to cover all known mutations
(550 bp apart) conferring ML-resistant genotypes found in vivo: the first
assay was able to detect single base mutations at positions 2063, 2064 and
2067, while the second detected the mutation at position 2617. The proto-
col described17 was modified by increasing the number of cycles to 45 for
both primary and secondary PCR and by adding 2 lL of template for the
secondary PCR. The presence of the targeted DNA fragment was detected
by high-resolution capillary electrophoresis (QIAxcelV
R
Advanced System,
Qiagen), obtaining an approximately 165 bp fragment. Immobilization of
the biotinylated product and the pyrosequencing reaction were also per-
formed following the protocol of Spuesens et al.16 with the following modi-
fications: a total of 4 lL of streptavidin beads and 26lL of H2O per sample
were used, and the plates were mixed for 10 min instead of 15 min.
Pyrosequencing reactions and sequence analysis were also performed
using the PyromarkTMQ96MD sequencer (Biotage, Sweden) and associated
software.
Statistical analysis
Qualitative and categorical data were summarized with number and per-
centage, and were compared using a v2 test. Statistical analyses were per-
formed with the statistical free software PSPP (http://www.gnu.org/
software/pspp/, last accessed April 2020). Statistical significance was
accepted at P < 0.05.
Results
Molecular detection of M. pneumoniae
A total of 821 specimens (described in Table 1) were collected
from 774 individuals, corresponding to children in 769 cases (766
patients with suspicion of pneumonia or relatives with pneumonia,
and 3 healthy children) and adults in 52 cases (29 patients with a
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pneumonia diagnosis or their household contacts, and 23 volun-
teer health professionals). A positive detection of MP was obtained
in 138 (16.8%) specimens, corresponding to 127 individuals. One
positive specimen was excluded from the study due to insufficient
DNA; thus, the final count of positive specimens was 137 (16.7%,
3 by Progenie, 134 by Anyplex). Positive detections were mostly
from children (133, 97.1%), with only 4 (2.9%) from adults (close
relatives). The median age of children was 6.6 years and the high-
est proportion of positive samples was detected in children aged
>5 years (53.3%, 73/137), followed by children aged between 1
and 5 years (36.4%, 50/137) and 1 year old (7.3%, 10/137)
(Table 2). The majority of specimens were collected during the
middle years of the project (2014 and 2015), and the positivity
rates per year were as follows: 26% in 2013 (19/73), 19% in 2014
(49/258), 13.2% in 2015 (56/423) and 22.4% in 2016 (15/67), as
depicted in Figure 1(a).
Performance of molecular detection in comparison with
serological diagnosis
In parallel to PCR, serological diagnosis was also performed in 376
cases, including 105 patients with a positive MP detection by PCR
and 271 with a negative MP result. Among the 105 MP PCR-positive
subjects, serology results in the acute phase (first serum sample)
were also positive (antibody levels 1/160) in 75 (71.4%) cases,
whereas in the remaining 30 cases with negative serology (anti-
body levels <1/160), seroconversion was observed in 13 (43.3%)
patients in convalescence phase (second serum sample), leading
to 88 out of 105 patients (83.8%) with both positive serology and
PCR, and an overall agreement between techniques of 76%.
Among the 271 MP PCR-negative subjects, serology was also nega-
tive in 199 cases (73.4%). The remaining 72 cases showed a posi-
tive serology result in a single sample. Thus, sensitivity and
specificity of the PCR compared with serology was 55% and 92%,
respectively (Table 3).
M. pneumoniae MLVA typing
Eleven different MLVA types were identified; the most abundant
was 4-5-7-2 (70/137, 50.1%), followed by 3-5-6-2 (40/137,
29.2%), 3-6-6-2 (11/137, 8%), 4-5-6-2 (4/137, 2.9%), 3-5-7–2
(3/137, 2.2%), 4-5-5-2 (2/137, 1.5%), 4-5-7-3 (2/137, 1.5%), 4-6-
7-2 (2/137, 1.5%), 3-3-6-2 (1/137, 0.7%), 3-4-6-2 (1/137, 0.7%)
and 3-4-7-2 (1/137, 0.7%). The proportions of the types varied
widely between the years of the study (Figure 1b). Comparing the
2 years with higher numbers of positive cases (2014 and 2015,
Figure 1a), the proportion of type 4-5-7-2 during those years was
similar, while an increase of type 3-5-6-2 and a decrease of type
3-6-6-2 was observed from 2014 to 2015. Interestingly, the distri-
bution of the types also varied depending on the season
(Figure 1c), with genotype 4-5-7-2 mostly detected during sum-
mer (both 2014 and 2015) in contrast to type 3-5-6-2, which was
more frequent from winter 2014 to spring 2015. Genotype 3-6-6-2
also showed a peak during spring 2014, whereas the other minor-
ity genotypes were detected in similar numbers among all seasons
from spring 2013 to spring 2016.
The four positive specimens detected from adults had the
same MLVA profile as the children, suggesting transmission of MP
within the same household.
Twelve out of the 137 cases were reinfections after 1 or
2 months from the primary specimen. In 9 specimens, the MLVA
type detected was the same as the initial sample; however, for
2 patients, the MLVA changed. In one case, the initial MLVA was
3-6-6-2 (March 2015) but the MLVA from the specimens obtained
in April and May 2015 was 3-5-6-2. For the other case, the initial
type was 3-5-6-2 (March 2016) whereas the specimen obtained
on April 2016 was 3-5-7-2. Given that both isolates had only a
single repeat change from the initial profile, the second detected
specimen could be a variant of the first isolate.
Clinical findings
Several parameters such as chest radiography, axillary temp-
erature, respiratory rate, presence of adenopathy, arthralgia and
pleural effusion were recorded, and a statistical analysis was
performed to determine if there was a relationship to the MLVA
type. Results are shown in Table 2; however, none of the clinical
symptoms evaluated was related to a specific MLVA type.
Table 1. Classification of the patients and specimens included in this study
Samples tested for MP Age group Group of individuals
Number of
samples tested
Positive MP
detection (number)
Complementary
data
821 specimens
(774 individuals)
Children
(<18 years old)
Children with suspicion of
pneumonia or relatives with
pneumonia
766a 17.5% (134)a 131 patients
2 household
contacts
1 classmate
Healthy children 3 0.0% (0)
Adults Adults with diagnosis of
pneumonia or close relatives
with pneumonia
29 13.8% (4) 2 patients
2 relatives
Healthy adults (volunteer
healthcare professionals)
23 0.0% (0)
aFor one specimen where MP was detected by PCR, it was not possible to perform the MLVA typing due to insufficient DNA. Thus, the total number of
specimens from children typed was 133.
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Viral infections were also evaluated in MP-positive
patients. Respiratory viruses were found in 45.3% of patients
(N = 62), with two or more viruses detected in 12.4% of the
cases. A total of 79 virus-positive samples were detected,
listed in Table 4. The most frequently detected was Rhinovirus
(37.9%, 30) followed by Parainfluenza virus (15.2%, 12) and
Respiratory Syncytial Virus (13.9%, 11). The genotypes 4-5-7-2
and 3-5-6-2 were the most frequently co-infected with virus
(P = 0.033).
MLr detection
The MP PCR-positive samples were further screened for point
mutations known to confer MLr, and they were detected in 11 sam-
ples (8%, 10 patients), showing four different types of mutation,
three of them in region 1 and one in region 2: A2063G (N = 7),
A2063T (N = 1), A2064G (N = 2) (region 1) and C2617A (N = 1)
(region 2).
Among the resistant strains, the most frequent MLVA type was
4-5-7-2 (N = 8), followed by 3-5-6-2 (N = 3), and all of them were
detected between 2014 and 2016. All the resistant strains
detected were linked to a previous treatment with MLs. In six
cases, patients developed the resistance during the treatment
of the studied episode, with a specimen before treatment
being susceptible to MLs and having the same MLVA profile as
the after-treatment and resistant specimen. In four cases, re-
sistant strains were collected after ML treatment during the
ongoing or a previous CAP episode. The last case was a patient
whose brother previously had CAP caused by MP and was sub-
sequently treated with MLs.
Table 2. Characteristics and clinical symptoms distributed by MLVA type identified
MLVA type
% (n) from total of
positive specimens
(N = 137) P value
Characteristic or
clinical symptoms
4-7-5-2
(N = 70)
3-5-6-2
(N = 40)
3-6-6-2
(N = 11)
Other
(N = 16)
Sex
male (n) 58.6% (41) 52.5% (21) 45.5% (5) 56.3% (9) 55.5% (76) 0.834
female (n) 41.4% (29) 47.5% (19) 54.5% (6) 43.7% (7) 44.53% (61)
Age group
1 year (n) 5.7% (4) 5.0% (2) 0.0% (0) 25.0% (4) 7.3% (10) 0.252
1–5 years (n) 38.6% (27) 40.0% (16) 36.4% (4) 18.6% (3) 36.4% (50)
>5 years (n) 51.4% (36) 52.5% (21) 63.6% (7) 56.2% (9) 53.3% (73)
adult (n) 2.2% (3) 0.73% (1) 0.0% (0) 0.0% (0) 2.9% (4)
Body temperature
afebrile (n) 54.3% (38) 57.5% (23) 81.8% (9) 50.0% (8) 57.0% (78) 0.348
fever/slight fever (n) 45.7% (32) 42.5% (17) 18.2% (2) 50.0% (8) 43.0% (59)
Respiratory rate
eupnoea (n) 70% (49) 72.5% (29) 81.82% (9) 68.75% (11) 71.5% (98) 0.857
tachypnoea (n) 30% (21) 27.5% (11) 18.18% (2) 31.25% (5) 28.5% (39)
Lung auscultation
normal (n) 45.7% (32) 47.5% (19) 72.73% (8) 37.5% (6) 47.5% (65) 0.316
altered (n) 54.29% (38) 52.5% (21) 27.27% (3) 62.5% (10) 52.5% (72)
Chest X-ray
normal (n) 2.9% (2) 10.0% (4) 0.0% (0) 6.2% (1) 5.1% (7) 0.655
pathological (n) 80.0% (56) 72.5% (29) 90.91% (10) 81.3% (13) 78.8% (108)
not performed (n) 17.1% (12) 17.5% (7) 9.1% (1) 12.5% (2) 16.1% (22)
Adenopathies
absent (n) 97.1% (68) 97.5% (39) 100.0% (11) 100.0% (16) 97.8% (134) 0.857
present (n) 2.9% (2) 2.5% (1) 0.0% (0) 0.0% (0) 2.2% (3)
Arthralgia
absent (n) 97.1% (68) 97.5% (39) 100.0% (11) 100.0% (16) 97.8% (134) 0.857
present (n) 2.9% (2) 2.5% (1) 0.0% (0) 0.0% (0) 2.2% (3)
Stevens–Johnson syndrome
absent (n) 98.57% (69) 97.5% (39) 100.0% (11) 100.0% (16) 98.5% (135) 0.873
present (n) 1.43% (1) 2.5% (1) 0.0% (0) 0.0% (0) 1.5% (2)
Viral coinfection
absent (n) 58.6% (41) 42.5% (17) 72.7% (8) 56.25% (9) 54.7% (75) 0.232
present (n) 41.4% (29) 57.5% (23) 27.3% (3) 43.75% (7) 45.3% (62)
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Discussion
M. pneumoniae is known to cause between 20% and 40%1 of
CAP in children and young adults, with increasing resistance to
MLs,13–20 which are the first-line treatment. Prevalence of MP CAP
in our region has not been widely studied yet, and, to the best of
our knowledge, this is the first study to document the MLVA types
circulating in our area as well as the MLr prevalence. During the
study period, a total of 137 (16.7%) specimens were positive
and could be further analysed for MLVA typing and MLr detection.
The proportion of positive samples detected is similar to that in
other European countries.21,30
During our study, a higher number of positive cases was
detected during 2014 and 2015 (Figure 1a), probably related to a
higher number of specimens processed. In accordance with similar
studies found in the literature,21 the highest proportion of positive
cases was in children older than 5 years (N = 73).
Culturing MP is usually performed in reference centres. Given
the prompt presence of IgM antibodies, especially in children, sero-
logical tests are the most often applied methods for MP diagnosis.
Different techniques have been used, such as complement fixation
tests, enzyme immunoassays or passive agglutination with
latex or gelatin particles, which have been extensively reviewed.1
Usually, two samples (from initial and convalescent phases) are
required to demonstrate the seroconversion and to increase the
diagnostic sensitivity, although some authors have found that
using only an acute phase sample could lead to a diagnosis
Table 3. Performance of molecular diagnosis compared with serology
for the detection of Mycoplasma pneumoniae
Serology
Positive Negative Total
PCR Positive 75/88a 30/17a 105
Negative 72 199 271
Total 147/160a 229/216a 376
Sensitivity 51%/55%a
Specificity 87%/92%a
Overall agreement 73%/76%a
aPatients that showed seroconversion (second serology with a positive
result). PCR performed from nasopharyngeal aspirates.
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Figure 1. Molecular detection and typing of M. pneumoniae. (a) Detected cases of M. pneumoniae distributed by year. (b) MLVA types identified dis-
tributed by year. (c) MLVA types identified distributed by season during the time frame of the study.
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in up to 50% of cases.31,32 In our comparison of serology and
molecular methods, we found an overall agreement of 73%
between both techniques during the acute phase (first serum
sample positive, antibody titre 1/160). After the seroconver-
sion of 13 patients, the overall agreement increased to 76%.
Discrepancies between these methods can be explained due
the nature of the techniques.33–35 Immunosuppressed patients
or collecting the serology specimen too early during the acute
phase could lead to false-negative results.36 On the other
hand, in the event of a previous MP infection, IgM can be
detected for months or even years.34,35 Kim et al.36 suggested
to set the positivity cut-off to a titre 1/640 for the diagnosis of
acute-phase CAP. In our study, in 61 out of the 72 serology-
positive–PCR-negative cases, their antibody titres were really
close to the cut-off value (22 with a titre of 1/160 with no in-
crease during the convalescent phase and 46 cases with a titre
of 1/320), which could indicate previous contact with MP and
thus be false positives for the current acute infection. On the
other hand, 17 patients had negative serology but positive mo-
lecular detection of MP. It has been reported that MP can colon-
ize the nasopharynx for a long time without any clinical
manifestation. Meyer Sauteur et al.37 detected MP DNA in 48%
of healthy children tested as controls during their study, and
Nilsson et al.33 were able to detect MP DNA for 7 weeks after the
clinical symptoms, even though the patients were correctly
treated with MLs. Further research would be necessary to clarify
the impact of carriers in the community on infection transmis-
sion. Molecular techniques can be valuable tools for MP diagno-
sis, and further allow the study of epidemic clusters by
performing molecular typing or the detection of resistance pat-
terns. Thus, combining serological methods with molecular
tools should improve MP diagnosis and avoid misinterpretation.
MLVA is a powerful genotyping tool that can be used to better
distinguish among strains.38 The genotypes 4-5-7-2 and 3-5-6-2
were the most abundant, as has been described in other
geographic areas such as Europe,39 the USA40 and China.10
Furthermore, those genotypes were seasonal, with 4-5-7-2 mainly
detected during summer whereas 3-5-6-2 was mainly circulating
during winter and spring. Minority genotypes were evenly distrib-
uted within seasons and the years of the study.
Clinical aspects in MP pneumonia can be subtle and shared with
other viral or bacterial entities. However, some clinical findings or
an altered X-ray test, showing only bilateral pneumonia (20% of
cases), could help in its diagnosis.1,41 Thus, the most reliable diag-
nostic is direct or indirect pathogen detection. Respiratory viruses
were also tested for in patients with a confirmed MP pneumonia.
In most cases we detected multiple viral coinfections, which com-
plicated distinguishing whether the observed clinical symptoms
were due to the virus or MP. This has been observed before, as
some studies have shown that different viruses, such as
Rhinovirus, could be found in children without any symptoms;42
thus their detection should be taken into consideration with some
caution. In our study, this virus was the most frequently detected.
However, it must be kept in mind that infections with other viruses
such as Parainfluenza or Respiratory Syncytial Virus could be
related to the clinical symptoms shared with MP.
In our study, no correlation was found between the MLVA type
and the different symptomatology, in contrast to what was
described by Yan et al.,43 where the MLVA was linked to the clinical
outcome, although this group also found that some MLVA types, ir-
respective of their susceptibility profile, showed a higher risk of pro-
gression to severe MP pneumonia.
MLs are the first-line treatment for children with MP pneumonia
in our country.44 Fluoroquinolones and tetracyclines are generally
avoided in this population due to their side effects,45 although
countries with high rates of ML-resistant strains (such as Japan)
have approved tosufloxacin or minocycline as second-line drugs
for children with MP pneumonia who respond poorly to MLs.46
Several studies reporting MLr have been published. The first resist-
ant strains were detected in Asia and were linked to broad ML
use,47 with resistance rates that vary between 13% and 100% in
China19,20,48–50 or Japan.8,51–53 Similarly, antibiotic pressure seems
to be the cause of the high resistance rate detected in Italy
(25.6%).26 Lower resistance rates have been described in other
European countries, such as 9.8% in France,13 9.3% in England,23
1.2% in Germany24 and 1% in Slovenia.21 Interestingly, no resist-
ant strains were detected in northern countries, such as Sweden.25
Table 4. Virus detecteda distributed by MLVA type identified
MLVA type
Virus 4-7-5-2 (N = 70) 3-5-6-2 (N = 40) 3-6-6-2 (N = 11) other (N = 16) Total
Influenza virus 28.6% (2) 28.6% (2) 0.0% (0) 42.8% (3) 8.9% (7)
Metapneumovirus 0.0% (0) 0.0% (0) 0.0% (0) 100% (1) 1.3% (1)
Parainfluenza virus 66.7% (8) 25.0% (3) 0.0% (0) 8.3% (1) 15.2% (12)
Respiratory Syncytial Virus 27.3% (3) 36.3% (4) 18.2% (2) 18.2% (2) 13.9% (11)
Rhinovirus 53.3% (16) 36.7% (11) 3.3% (1) 6.7% (2) 37.9% (30)
Adenovirus 50.0% (5) 50.0% (5) 0.0% (0) 0.0% (0) 12.7% (10)
Bocavirus 0.0% (0) 50.0% (1) 50.0% (1) 0.0% (0) 2.5% (2)
Coronavirus 0.0% (0) 100% (2) 0.0% (0) 0.0% (0) 2.5% (2)
Enterovirus 50.0% (2) 0.0% (0) 25.0% (1) 25.0% (1) 5.1% (4)
Total 45.6% (36) 35.4% (28) 6.3% (5) 12.7% (10) 100% (79)
aResults are shown as the percentage with virus detected (n).
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Eight percent of the strains tested had a point substitution in
domain V of the 23S rRNA gene that conferred resistance to MLs.
Interestingly, in 6 out of 11 patients, a shift to a resistant pattern
was detected from the initial to the second sample collected for
the clinical follow-up after ML treatment. It is important to high-
light that one of the resistant cases was resistant only after two
doses of MLs, as the treatment had to be interrupted due to an al-
lergic event. MLVA typing confirmed that it was probably the same
strain and not a reinfection with an already resistant strain. Given
that the MLr found in vivo is mainly linked to point mutations in do-
main V of the 23S rRNA,45 only that region was analysed. However,
the real impact on the MLr phenotype of mutation on L4 and L22
ribosomal proteins remains unclear,4,9 and it should be addressed
with further studies.
The rising incidence of ML-resistant strains favoured by a previ-
ous ML treatment is a significant finding. Interestingly, symptom
clearance was observed in all ML-resistant CAP cases even after
maintaining ML as antibiotic therapy.
This study had several limitations. First, sera and nasopharyn-
geal aspirate were simultaneously collected for MP serological and
molecular diagnosis, respectively. Thus, when the CAP was sus-
pected to be caused by a virus, there were no sera available to per-
form a serological diagnosis of MP, which would have given a more
accurate comparison between the two techniques. Secondly, even
though the number of specimens investigated was high (N = 821),
the final number of specimens positive for MP was relatively small
for statistical purposes (N = 137). Thirdly, this study only covers a
small area of Spain. It would be interesting to perform a multi-
centre study to include several regions of our country in order to
corroborate our findings, preferably during an extended period
to determine the occurrence of infection peaks in our area and to
confirm the distribution of the observed MLVA types.
In conclusion, we have described the first evaluation of
M. pneumoniae MLVA types circulating in our area. The most abun-
dant types found were 4-5-7-2 and 3–5-6-2, with an MLr rate of
8%. Given that the clinical course of CAP usually resolves spontan-
eously, and MLs are extensively employed in children, it should be
reconsidered whether the treatment is suitable in all cases, as it
may unnecessarily increase MLr.
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